"Glycine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.
| Descriptor ID |
D005998
|
| MeSH Number(s) |
D12.125.481
|
| Concept/Terms |
Glycine- Glycine
- Aminoacetic Acid
- Acid, Aminoacetic
|
Below are MeSH descriptors whose meaning is more general than "Glycine".
Below are MeSH descriptors whose meaning is more specific than "Glycine".
This graph shows the total number of publications written about "Glycine" by people in this website by year, and whether "Glycine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 2 | 3 |
| 1994 | 0 | 1 | 1 |
| 1995 | 2 | 1 | 3 |
| 1998 | 2 | 1 | 3 |
| 1999 | 0 | 1 | 1 |
| 2000 | 2 | 2 | 4 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 1 | 4 |
| 2006 | 3 | 0 | 3 |
| 2007 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 2 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 4 | 4 |
| 2020 | 0 | 3 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glycine" by people in Profiles.
-
Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy. Eur Heart J. 2022 09 21; 43(36):3477-3489.
-
Structural basis for cannabinoid-induced potentiation of alpha1-glycine receptors in lipid nanodiscs. Nat Commun. 2022 08 18; 13(1):4862.
-
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 06 01; 182(6):592-602.
-
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol. 2021 Nov 01; 7(11):1669-1677.
-
A C. elegans model of C9orf72-associated ALS/FTD uncovers a conserved role for eIF2D in RAN translation. Nat Commun. 2021 10 15; 12(1):6025.
-
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 04 01; 137(13):1792-1803.
-
TGF-? Promotes Metabolic Reprogramming in Lung Fibroblasts via mTORC1-dependent ATF4 Activation. Am J Respir Cell Mol Biol. 2020 11; 63(5):601-612.
-
Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank. Br J Cancer. 2020 10; 123(9):1356-1359.
-
Mechanisms of activation and desensitization of full-length glycine receptor in lipid nanodiscs. Nat Commun. 2020 07 27; 11(1):3752.
-
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807.